Myeloproliferative disorders include several different conditions that are characterized by excess production of blood cells ...

Treatment can involve targeted medications or careful monitoring. Myeloproliferative disorders are a group of cancers involving the uncontrolled replication of cells derived from myeloid stem cells.

The individual behavior of a patient’s myeloproliferative neoplasm (MPN) will determine how the disease is monitored and ...

One research noted the persistent efforts to develop new treatments for myeloproliferative neoplasms (MPNs), a commitment ...

Veliparib ER is under clinical development by AbbVie and currently in Phase II for Myeloproliferative Disorders.

For several years, investigators have been studying combinations that include ruxolitinib, sold as Jakafi, to treat ...

HMPL-306 is under clinical development by Hutchison MediPharma and currently in Phase I for Myeloproliferative Disorders.

Polycythemia vera and essential thrombocythemia are the most common chronic myeloproliferative neoplasms ... are pushing therapeutic goals from disease control only to cure.